perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



#### 22 \* Corresponding author

23 E-mail: tlil@inu.edu.cn.

24

25 † Shujun Sun and Yiyong Wen have contributed equally to this work.

26

# <sup>27</sup> **Abstract**

28 **Background:** Herpesvirus infections may trigger Autoimmune neuroinflammatory 29 diseases (ANDs), but their causal role is uncertain. This study used Mendelian 30 randomization (MR) to investigate the causal effects of herpesvirus antibodies on ANDs. 31 **Methods:** We assessed 22 herpesvirus antibodies and five ANDs—multiple sclerosis 32 (MS), neuromyelitis optica (NMO), myasthenia gravis (MG), Guillain-Barr é syndrome 33 (GBS), and chronic inflammatory demyelinating polyneuropathy (CIDP)—using five MR 34 methods. MR-PRESSO, MR-Egger, and Cochran's Q statistic identified pleiotropy and 35 heterogeneity. Bonferroni correction set the significance threshold at P<4.545e-04. 36 Validation used UK Biobank and FinnGen data, with meta-analysis for inconsistent 37 results. **Results:** Significant positive causal effects were found for Epstein-Barr virus 38 encoded nuclear antigen-1 (EBV EBNA-1) (OR=3.009), EBV viral capsid antigen (VCA) 39 p18 (OR=8.700), and human herpesvirus 7(HHV7) U14 (OR=3.359) antibody levels 40 on MS risk, and HHV7 U14 (OR=10.641), Varicella zoster virus glycoprotein E and 41 glycoprotein I(VZV gE and gI) (OR=17.220) antibody levels on NMO risk. VZV gE and gI 42 (OR=2.542) antibodies increased MG risk, while EBV ZEBRA (OR=0.592) reduced 43 MS risk. Negative effects of EBV EA-D and ZEBRA antibodies on NMO were also noted.

44 Validation confirmed the effects of EBV EBNA-1, EBV VCA p18 antibodies on MS, and 45 VZV gE and gI on antibody MG, while EBV ZEBRA and HHV7 U14 antibodies effects on 46 MS were not validated. **Conclusions:** The study suggests a causal link between specific 47 herpesvirus antibodies and the risk of MS, NMO, and MG. 48 49 **Kewords:** Autoimmune neuroinflammatory diseases, multiple sclerosis, neuromyelitis

50 optica, myasthenia gravis, Epstein-Barr virus, human herpesvirus, varicella zoster virus, 51 antibody

52

# <sup>53</sup> **Introduction**

54 Autoimmune neuroinflammatory diseases (ANDs) are a category of disorders in 55 which the immune system mistakenly targets and attacks the nervous system, resulting 56 in inevitable structural and functional damage[1, 2]. Autoimmune neurological diseases 57 (ANDs) include mainly multiple sclerosis (MS), neuromyelitis optica (NMO), Guillain-Barr 58 é syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and 59 myasthenia gravis (MG). MS and NMO affect the central nervous system (CNS), GBS 60 and CIDP affect the peripheral nervous system (PNS), and MG affects the 61 neuromuscular junction (NMJ). These conditions lead to neuronal or axonal damage, 62 demyelination, damage to the nerve-muscle junction and other pathological changes [3, 63 4].

64 The incidence and prevalence of autoimmune diseases are increasing worldwide 65 every year, but the exact causes of these diseases remain unknown; however, it is

66 thought that a mixture of genetic and environmental factors play a role in their 67 development [5]. Infections seem to be a common trigger for autoimmune diseases [6].

68 Several viruses of the Herpesviridae family have been implicated as an important 69 risk factor for ANDs, Epstein-Barr virus (EBV) has been implicated as a major cause of 70 multiple sclerosis [7], the risk of MS increases 32-fold following infection with EBV [8]. 71 Human herpesvirus 6A (HHV-6A) has been associated with a higher risk of developing 72 multiple sclerosis. Cytomegalovirus (CMV) infection may be associated with the 73 occurrence of aquaporin-4 antibody-positive NMO spectrum disorder (AQP4 IgG+ 74 NMOSD) [9]. CMV and EBV are also frequently identified as antecedent pathogens of 75 GBS [10]. Case reports of CIDP have found associations with CMV and EBV [11].

76 The association between EBV infection and the pathogenesis of MG remains 77 controversial [12, 13]. Meanwhile, the associations between viruses of the Herpesviridae 78 family and MG remain unclear. Existing observational studies and case reports have 79 limited sample sizes, which reduces the statistical power to detect true associations and 80 increases the likelihood of random error. In addition, it is difficult to draw causal 81 conclusions from observational evidence due to residual confounding and reverse 82 causation [14].

83 Mendelian randomisation (MR) is a novel approach that may offer more effective 84 solutions to the above shortcomings. MR uses genetic variations that affect exposure as 85 instrumental variables (IVs) to assess the causal relationship between exposure and 86 outcomes. Because alleles are randomly assigned at conception, they are unaffected by 87 confounding factors and disease states. By using genetic variants as IVs, MR can reduce

88 the confounding effects of environmental factors and avoid reverse causation bias [15, 89 16].

90 Previous MR studies have found no association between herpes simplex virus (HSV) 91 infection and MS [17], whereas varicella infection is associated with MS [18]. Compared 92 to viral infections, antibody immune responses may not only serve as markers of infection 93 exposure, but also potentially provide clues to the pathophysiological mechanisms 94 associated with ANDs. However, whether there is a causal relationship between these 95 common herpesvirus-induced antibody immune responses and ANDs is unknown, and to 96 the best of our knowledge, our study will be the first to investigate the causal relationship 97 between herpesvirus antibodies and ANDs, thereby further exploring new potential 98 therapeutic targets and potentially informing vaccine selection for patients with ANDs.

# <sup>99</sup> **Materials and Methods**

#### <sup>100</sup> **Study Design**

101 MR analysis is a statistical technique used to identify causal relationships, 102 particularly within observational data. It uses genetic variants that influence exposure as 103 instrumental variables (IVs) to assess the causal relationship between exposure and 104 outcomes. A key advantage of MR analysis is its ability to mitigate bias arising from 105 confounding and reverse causation, as genetic variations are generally not influenced by 106 environmental or behavioural factors [15, 16]. MR studies will help to overcome current 107 obstacles in investigating the relationship between antibody immune responses following 108 herpesvirus infection and various ANDs, thus facilitating a more accurate investigation of 109 direct causal relationships.

## <sup>110</sup> **Data Source**

111 Our study investigated the immune response of 22 antibodies to five types of 112 herpesvirus infection: Anti-CMV IgG seropositivity, CMV pp28 antibody levels, CMV pp52 113 antibody levels, CMV pp150 antibody levels; Anti-EBV IgG seropositivity, EBV early 114 antigen-D (EA-D) antibody levels, EBV encoded nuclear antigen-1 (EBNA-1) antibody 115 levels, EBV viral capsid antigen (VCA) p18 antibody levels, EBV ZEBRA antibody levels; 116 Anti-HHV6 IgG seropositivity, Anti-HHV6 IE1A IgG seropositivity, HHV6 IE1A antibody 117 level, Anti-HHV6 IE1B IgG seropositivity, HHV6 IE1B antibody level, HHV6 p101k 118 antibody level, Anti-HHV7 IgG seropositivity, HHV7 U14 antibody levels, Anti-HSV1 IgG 119 seropositivity, HSV1 mgG-1 antibody levels, Anti-HSV2 IgG seropositivity, HSV2 mgG-1 120 antibody levels; Varicella zoster virus glycoprotein E and I (VZV gE and gI) antibody 121 levels.

122 The above immune responses were investigated in a Genome-Wide Association 123 Study (GWAS) involving a total of 8,735 individuals for case-control phenotypes and an 124 average (range) of 4,286 (276-8,555) samples per quantitative analysis [19].

125 Genome-wide summary data for MS consisting of 47,429 cases and 68,374 controls 126 from the European population were obtained from the International MS Genetics 127 Consortium (IMSGC) [20]. To further validate the positive results, UK Biobank (1679 128 cases and 461254 controls, https://gwas.mrcieu.ac.uk/datasets/ukb-b-17670/) and 129 FinnGen (2620 cases and 449770 controls, https://r11.finngen.fi/pheno/G6\_MS) for MS 130 were used.

131 NMO-related GWAS data were obtained from the largest and most recent NMO

132 GWAS meta-analysis, which included 215 NMO cases and 1,244 controls [21].



141 For GBS, data were obtained from the FinnGen Biobank with 489 cases and 445865 142 controls (https://r11.finngen.fi/pheno/G6\_GUILBAR). Genetic associations for CIDP were 143 derived from 456,348 individuals of European ancestry from the UK Biobank using a fast 144 genome-wide association generalised linear mixed model and were obtained from the 145 catalogue [23]. Detailed information of Data used in our study was shown in 146 supplementary table 1.

## <sup>147</sup> **Instrumental Variable Selection**

148 We screened single nucleotide polymorphisms (SNPs) that showed a significant 149 association with exposure factors in the exposure GWAS ( $P < 5 \times 10$ -8). When the 150 number of SNPs was less than 10, we relaxed the SNPs selection criterion to a p-value 151 threshold of p<1e-07 or p<1e-06, with a minimum standard of p<1e-05 [24]. SNPs with 152 minor allele frequencies (MAF < 0.01) were also deleted, and linkage disequilibrium (LD) 153 between SNPs was resolved by clustering (R2<0.001 within a 10 Mkb clustering

154 distance). Palindromic SNPs were removed. The exposure and outcome data sets were 155 then harmonised. The proportion of variance explained by instrumental variables was 156 calculated using the formula:  $R2 = 2 \times 82 \times EAF \times (1 - EAF)/(2 \times 82 \times EAF \times (1 - EAF) +$ 157 2  $\times$  SE2  $\times$  N  $\times$  EAF  $\times$  (1 - EAF)), where N is the sample size [25]. The power of the 158 genetic instrument was assessed using the F-statistic, calculated as F= R2  $\times$  (N - 2)/(1 -159 R2). An F-statistic greater than 10 indicates a strong instrument, IVs with F-statistics less 160 than 10 were considered weak and thus excluded from the analysis. The 161 SNiPA(https://snipa.org/snipa3/) and GWAS catalogue(https://www.ebi.ac.uk/gwas/home) 162 was used to check that the SNPs were not associated with other relevant confounders, 163 such as smoking, body mass index (BMI), physical activity, serum 25-hydroxyvitamin D 164 levels.

# <sup>165</sup> **Mendelian Randomization Analysis**

166 When there was only one IV, the Wald ratio method was utilized. In cases where two 167 IVs were present, Inverse Variance Weighted (IVW) method will be used. With more than 168 two instrumental variables (IVs) available, univariable Two-Sample MR (TSMR) was 169 used to estimate the total causal effects of antibody immune response on ANDs, we 170 applied five MR analysis methods: IVW, MR Egger, Weighted Median, Simple Mode, and 171 Weighted Mode, IVW served as the primary approach for result interpretation [26].

172 To clarify whether there were reverse causal relationships between ANDs and 173 antibody immune responses, we also conducted reverse Mendelian randomization.

174 To account for multiple comparisons, the Bonferroni correction was utilized. We set a 175 significance threshold of  $\alpha = 0.05/n$  (where n represents the number of comparisons) to

176 mitigate the increased risk of false positives from multiple testing [27]. This correction 177 method helps maintain the overall Type I error rate at an acceptable level while 178 controlling for the familywise error rate. Therefore, a P-value below 4.55E-04 (calculated 179 as 0.05 divided by the product of 22 comparisons and 5 outcomes) was considered 180 statistically significant.

181 MR Egger intercept test and Outlier (MR-PRESSO) were used to detect the 182 presence of pleiotropy, When the P-values for MR Egger intercept and MR-PRESSO are 183 less than or equal to 0.05, it suggests the presence of pleiotropic IVs. To address this, we 184 iteratively performed MR Egger intercept and MR-PRESSO tests, removing any outliers 185 each time, until no horizontal pleiotropy was detected. Furthermore, we also employed 186 visual inspection of the scatter plot and forest plot to test the MR " no horizontal 187 pleiotropy " . Additionally, Cochran ' s Q statistic was used to assess the degree of 188 heterogeneity among all IVs. P-value from the Q-test greater than 0.05 indicates that 189 there is no significant heterogeneity among the IVs.

190 To assess the robustness of the identified causal associations, we conducted two 191 sensitivity analyses: the MR-Egger intercept test and leave-one-out analysis. The 192 intercept from the MR-Egger test estimates the degree of directional pleiotropy, while the 193 leave-one-out analysis determines if the significant results are influenced by any single 194 SNP.

#### <sup>195</sup> **Meta-analysis**

196 For MS and MG, when the MR results of the discovery and replication phases were 197 inconsistent, the meta-analysis was performed to assess combined causality. The choice

- 198 of effect model was based on the heterogeneity of the results. If there was little significant
- 199 heterogeneity with  $12 \le 50\%$ , the fixed-effects model was used to combine the results.

200 Otherwise, the random effects model was used.

201 The statistical analyses in this study were performed using R version 4.4.1, including 202 TwoSampleMR, MRPRESSO and Metafor. The study protocol and details were not pre-

203 registered

<sup>204</sup> **Results**

# <sup>205</sup> **Selection of Instrumental Variables**

206 Detailed information on the IVs of antibody immune responses to five types of 207 herpesvirus is shown in Supplementary Table 2. The P value thresholds for anti-CMV 208 IgG seropositivity, CMV pp28 antibody levels, CMV pp52 antibody levels , CMV pp150 209 antibody levels, anti-EBV IgG seropositivity, anti-HHV6 IgG seropositivity, anti-HHV6 210 IE1A IgG seropositivity, HHV6 IE1A antibody levels, anti-HHV6 IE1B IgG seropositivity, 211 HHV6 IE1B antibody levels, HPV6 p101k antibody levels, anti-HHV7 IgG seropositivity, 212 anti-HSV 1 IgG seropositivity, HSV1 mgG-1 antibody levels anti-HSV2 IgG seropositivity 213 and HSV2 mgG-1 antibody levels were 1e-05,HHV7 U14 antibody levels were 1e-07, 214 EBV EA-D antibody levels, EBV EBNA-1 antibody levels, EBV VCA p18 antibody levels, 215 EBV ZEBRA antibody levels and VZV gE and gI antibody levels were 5e-08. rs1808192 216 in HHV7 U14 antibody levels, rs34811474 in anti-HSV 1 IgG seropositivity and 217 rs13204572 in VZV gE and gI antibody levels were deleted as they were associated with 218 BMI. IVs for MS, NMO, MG, CIDP, GBS are shown in Supplementary Tables 3, 5, 7, 9, 219 11, respectively. All F values of the IVs were greater than 10, indicating that weak

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

220 instruments were excluded.

# <sup>221</sup> **Antibody Immune Response Following Herpesvirus**  <sup>222</sup> **Infection on MS**

223 In this study, the antibody unit was the logarithmic transformation of the antibody median 224 fluorescence intensity. We observed a causal effect of a 1-unit increase in EBV EBNA-1 225 antibody levels, EBV VCA p18 antibody levels and HHV7 U14 antibody levels correlating 226 with an increasing risk of MS [IVW: odds ratio (OR) = 3. 009, 95% CI: 2.377-3.807, 227 P=4.772e-20, adjusted p=2.250e-18; IVW: OR=8.700, 95% CI: 6.128-12.351, P=1.059e-228 33, adjusted p=1.165e-31 and IVW: OR=3.359, 95%CI: 2.034-5.546, P=2.187e-06, 229 adjusted p=2.406e-04]. In addition, causal evidence was also found for a differential 230 effect of a 1-unit increase in EBV ZEBRA antibody levels (IVW: OR = 0.592, 95% CI: 231 0.491-0.713,  $P = 3.195e-08$ , adjusted p = 3.515e-6), the analysis did not reveal causal 232 relationships between other antibodies and the risk of MS (Fig 1, S Table 4). To validate 233 the above results, we also used the UK Biobank and FinnGen MS datasets, with detailed 234 results shown in Table 1. In all three datasets, the causal effects of EBV EBNA antibody 235 levels and EBV VCA p18 antibody levels on MS were significant; however, the MR 236 results of HHV7 U14 antibody levels and EBV ZEBRA antibody levels on MS differed 237 between the three datasets, and the meta-analysis did not confirm that the overall effects 238 of these on MS were significant.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



#### 239

#### 240 **Fig 1:**MR estimate results of antibodies of five herpesviridae viruses on MS.

241 Table 1. Mendelian Randomization Analysis of the Causal Effects of Herpesvirus Antibodies on





Toal REMA  $0.807(0.587 - 1.109)$  0.125

Heterogeneity:  $I^2=91.96\%$ ,  $\tau^2=0.070$ ,  $P< 0.05$ 

243 **Abbreviations:** MS: multiple sclerosis: EBV: Epstein-Barr virus; HHV: human herpes virus; IVW: IVW: inverse

244 variance weighted; REMA: Random Effects Meta-Analysis.

# <sup>245</sup> **Pleiotropy and Sensitivity Analysis for MS**

246 Heterogeneity was observed among the IVs of EBV EBNA-1 antibody levels 247 (Q=27.055 P=1.414e-4), EBV VCA p18 antibody levels (Q=70.545 P=1.147e-12), HHV6 248 IE1A antibody levels (Q=17.036 P=0.048) and anti-HSV2 IgG seropositivity (Q=13.885 249 P=0.031) in terms of their effect on MS (S Table 4). All p-values from the MR Egger 250 intercepts and MR-PRESSO global tests were greater than 0.05, indicating the absence 251 of outlier SNPs and no evidence of horizontal pleiotropy between the IVs and outcomes. 252 Leave-one-out analysis showed that the results remained consistent regardless of which 253 individual SNP was excluded (S Fig 1-22). 254 It is noteworthy that the final IVs of HHV7 U14 antibody levels and Varicella zoster 255 virus glycoproteins E and I (VZV gE and gI) antibody levels, filtered by the above steps,

256 consist of only two SNPs. IVs of the former have no heterogeneity (Q=2.823 P=0.093), 257 single SNP MR analysis showed the similar result (rs7773105: P=2.175e-05, adjusted 258 P=0.002, OR=2.562, 95%CI:1.660-3.956; rs805282: P=3.911e-12, adjusted P=4.300e-11, 259 OR=4.277, 95%CI: 2.97-6.448), we consider the causal relationship between HHV7 U14 260 antibody levels and MS to be reliable. However, there was significant heterogeneity 261 between these two IVs of VZV gE and gI antibody levels (Q= 53.561 P= 2.507e-13). In 262 the single SNP MR analysis, the significance of the effects of these two IVs on MS varied

263 (rs9270551: P = 2.78E-276, adjusted P = 3.058e-274, OR = 0.557e-06, 95% CI: 0.369e-264 03 - 0.843e-03; rs9272285: P = 1.052E-03, adjusted P = 0.116, OR = 0.106, 95% CI: 265 0.028-0.406). In particular, rs9270551 was strongly associated with MS (P = 1E-200), 266 suggesting the presence of horizontal pleiotropy. Therefore, based on the MISGC 267 databases, we used rs9272285 as an IV for VZV gE and gI antibody levels for MS. To

268 further investigate the association between VZV gE and gI antibody levels and MS, we

269 also performed MR analysis based on the MS datasets in UK Biobank and FinnGen with

270 the following results: OR (95%CI) =1.000(0.999-1.001), P=0.299 (UK Biobank),

271 0.2171830962485 OR (95%CI) =0.820 (0.5978-1.124) P=0.217 (FinnGen), so there

272 wasn't the causal relationship between VZV gE and gI antibody levels and MS.

## <sup>273</sup> **MS on Antibody Immune Response**

274 Reverse Mendelian randomization revealed that MS does not have significant 275 reverse causal effects on antibodies to the aforementioned herpesvirus antigens, with all 276 p-values greater than the adjusted p-value (4.550e-04) (S Fig 23).

# <sup>277</sup> **Antibody Immune Response on NMO**

278 There is a causal relationship between elevated levels of two EBV-related antibodies 279 and a reduced risk of NMO. These two antibodies are EBV EA-D antibody levels (IVW: 280 OR = 0.043 95% CI: 0.010-0.196, P = 4.546e-05, adjusted p=0.005) and EBV ZEBRA 281 antibody levels (IVW: OR = 0.079, 95% CI: 0.043-0.147, P = 7.587e-16, adjusted p=8. 282 345e-14). Conversely, an increased risk of NMO could be caused by higher antibody 283 levels of HHV7 U14 (IVW: OR =10.641 95% CI: 3.025-37.429, P=2.285e-04 adjusted 284 p=0.025) or VZV gE and gI (IVW: OR =17.220 95% CI: 9.760-30.380, P=8.727e-23

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

285 adjusted p=9.599e-21). Antibodies to other viruses of the Herpesviridae family had no

286 causal effect on the risk of NMO (Fig 2, S Table 6).



287

288 **Fig 2** MR estimate results of antibodies of five herpesviridae viruses on NMO.

# <sup>289</sup> **Pleiotropy and Sensitivity Analysis for NMO**

290 Heterogeneity was observed in the IVs for EBV EA-D antibody levels (Q=6.892, 291 P=0.075), EBV EBNA-1 antibody levels (Q=70.545, P=6.776e-4), EBV ZEBRA antibody 292 levels (Q=34. 471, P=0.011), HHV6 IE1A antibody levels (Q=29.584, P=0.042) and 293 HHV6 IE1B antibody levels (Q=31.661, P=0.034) on NMO (Supplementary Table 6). The 294 MR-PRESSO global test indicated the presence of horizontal pleiotropy between the IVs 295 for EBV EBNA-1 antibody levels on NMO (P=0.001), EBV ZEBRA antibody levels 296 (P=0.022) and HHV6 IE1B antibody levels (P=0.034). However, the p-values of the 297 Egger intercept were greater than 0.05 and no significant outliers were detected. The 298 leave-one-out analysis confirmed that no single SNP significantly altered the overall

299 results. Therefore, the results still have some informative value.



306 ZEBRA antibody levels and NMO.

307 Pleiotropy tests for the IVs of other antibodies showed no outlier SNPs and no

308 evidence of horizontal pleiotropy between them and the outcomes (Supplementary Table

309 6). Leave-one-out analysis consistently showed that excluding any single SNP did not

310 affect the results (S Fig 1-22).

## <sup>311</sup> **NMO on Antibody Immune Response**

312 Reverse causal effects of NMO on antibodies were not found (S Fig 24).

# <sup>313</sup> **Antibody Immune Response on MG**

314 We found a causal effect between increased VZV gE and gI antibody levels and an 315 increased risk of MG (IVW: OR = 2.542 95% CI: 1.972-3.277, P =5.897e-13 adjusted p= 316 2.594e-12). No significant associations were found between other antibodies and MG 317 (Fig 3). In addition, the UK Biobank and FinnGen MG datasets were used to validate this 318 result, with detailed results shown in Table 2. In all three datasets, the causal effect of 319 VZV gE and gI antibody levels on MG was all significant.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



320

- 321 **Fig 3** MR estimate results of antibodies of five herpesviridae viruses on MG.
- 322 **Table 2.** MR estimate results of antibodies of VZV gE and gI antibody levels on MG.



323 **Abbreviations:** MG: myasthenia gravi; VZV: varicella zoster virus; IVW: inverse variance

324 weighted; REMA: random effects meta-Analysis.

# <sup>325</sup> **Pleiotropy and Sensitivity Analysis for MG**

326 IVs of EBV EA-D antibody levels (Q=44.715, P=0.004) and EBV ZEBRA antibody 327 levels (Q=37.615, P=0.004) show significant heterogeneity (Supplementary Table 8). 328 Although MR-PRESSO identified pleiotropy, the Egger intercept did not indicate

- 329 significant pleiotropy and no significant outliers were detected. IVs from other antibodies
- 330 did not show heterogeneity and pleiotropy (S Table 8). The leave-one-out analysis gave
- 331 similar results, even after excluding individual SNPs (S Fig 1-22).
- <sup>332</sup> **MG on Antibody Immune Responses**
- 333 The adjusted P values from the MR analysis indicated that there was no causal 334 relationship between MG and any of the 22 types of antibody immune response (S Fig 335 24).
- <sup>336</sup> **Causal Relationships Detected Between Antibody**  <sup>337</sup> **Immune Responses and GBS/CIDP**
- 338 We found no forward or reverse causal relationships between the 22 antibody 339 immune responses to five types of herpesviruses and GBS and CIDP (Fig 4-5; S Fig 26-340 27). IVs for HSV1 mgG-1 antibody levels on CIDP showed heterogeneity (Q = 44.905, P  $341 = 0.03$  (S Table 12). Pleiotropy was detected by MR-PRESSO but not by the Egger 342 intercept, and the MR-PRESSO global test did not identify any significant outliers. Leave-343 one-out analysis showed no significant differences in MR results after removing individual 344 SNPs (S Fig 1-22).

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



#### 

#### **Fig 4** MR estimate results of antibodies of five herpesviridae viruses on GBS.



**Fig 5** MR estimate results of antibodies of five herpesviridae viruses on CIDP.

349 All other results, including those for GBS and CIDP, passed the heterogeneity and 350 pleiotropy tests. The sensitivity analysis did not identify any SNPs that significantly 351 affected the overall results.

<sup>352</sup> **Dicussion**

353 As the MR results showed, EBV EBNA-1 antibody and VCA p18 antibody were 354 positively correlated with MS. Levels of EBV ZEBRA antibody were negatively correlated 355 with MS in the IMSGC and UK Biobank datasets, but not in FinnGen, and the meta-356 analyses did not confirm a causal relationship. In addition, HHV7 U14 antibody levels 357 were positively associated with MS in the IMSGC dataset, but not in the UK Biobank or 358 FinnGen datasets, and the overall causal relationship was not established by the meta-359 analyses.

360 Negative associations between EBV ZEBRA and EA-D antibody levels and NMO 361 were shown in this study. Conversely, a positive association was found between NMO 362 and antibody levels of VZV gE, VZV gI and HHV7 U14. VZV gE and gI antibody levels 363 showed a positive association with MG.

364 The above results suggest an important role for EBV antigen-associated antibodies in 365 the pathogenesis of AND. EBV infects and persists in human B cells by exploiting the B 366 cell environment to sustain its life cycle while evading the host immune system through 367 minimal expression of viral proteins [28]. Several antibodies to EBV proteins can be 368 detected in EBV carriers. These proteins include EBNA-1 (BKRF1), a latency protein; 369 VCA p18 (BFRF3), a structural protein of the mature virus; ZEBRA (BZLF1), a lytic cycle 370 protein; and EA-D, a basic component of the viral DNA replication complex. [28, 29].

371 Previous studies have confirmed that higher antibody levels against EBNA-1 and VCA 372 p18 (or VCA) are associated with an increased risk of MS; in individuals with genetic 373 factors associated with lower EBNA-1 IgG titres, the onset of MS was delayed by 3.5 374 years [30, 31], [32]. A region within the carboxyl half of EBNA1 (amino acids 385-420) 375 induces elevated antibody levels in MS patients and shows the strongest association with 376 MS risk compared to antibody levels against other domains of EBNA1 [33]. EBNA1- 377 specific antibodies are found in the cerebrospinal fluid (CSF) of some MS patients; these 378 antibodies may play a role in the formation of oligoclonal bands, which are antibodies 379 produced by clonal B-cell-derived plasma cells in the central nervous system and are a 380 hallmark of MS [34]. Injection of a peptide derived from the aa395-420 region of EBNA1 381 into mice with experimental autoimmune encephalomyelitis (EAE) exacerbated CNS 382 autoimmunity [34, 35].

383 Our research confirms a causal relationship between antibodies to EBNA-1 or VCA p18 384 and MS. However, the exact mechanisms by which these two antibodies cause MS are 385 not yet clear. Based on the current evidence, molecular mimicry of EBNA-1 and VCA 386 p18 may play some role.Antibodies against VCA p18 (BFRF3) cross-react with the 387 cytoplasmic protein septin-9 [36]. Septin-9, a cytoplasmic protein that forms filaments, 388 may play a role in cytokinesis, exocytosis, neurite outgrowth and cell cycle control. While 389 it is widely expressed in various tissues, it is emerging as an intriguing candidate 390 autoantigen for MS due to gene mutations that cause hereditary neuralgic amyotrophy 391 [37]. In the CNS, septin-9 is mainly found in neurons and its expression is upregulated 392 after trauma [38]. Antibodies to EBNA1 have been observed to cross-react with

393 anoctamin 2, ɑB-crystallin, myelin basic protein (MBP) and glial cell adhesion molecule 394 [33, 34, 39]. However, the pathogenic role of these antibodies remains unclear because 395 successful cell-depleting therapy for MS does not affect antibody-producing plasma cells 396 in the short term. Moreover, such treatment does not seem to reduce oligoclonal bands 397 [7]. These two antibodies may become new therapeutic targets in MS, particularly in 398 patient groups with high levels of these antibodies and poor response to other treatments. 399 ZEBRA (BZLF1) was considered to be a major environmental factor associated with 400 MS and a significant contributor to the disease process [40]. BZLF1 was found in 46% of 401 MS brains, mainly associated with chronic lesions, and in 44% of non-MS brain tissue 402 [41]. ZEBRA is recognised as one of the viral immediate early genes that play an 403 important role in the transition of EBV from latency to lytic replication [42], Reactivation of 404 latent EBV infection is associated with disease activity in MS patients; however, research 405 results are controversial [43-45]. Meanwhile, increasing EBV ZEBRA antibodies have not 406 been found in MS [46], the role of ZEBRA antibodies in MS remains unclear.

407 Previous research found that anti-EA seropositivity was significantly higher in the 408 NMOSD group compared to the HC group and MS patients [47, 48], but another study 409 suggested that exposure to Epstein-Barr virus was not associated with an increased 410 likelihood of NMO compared to healthy subjects [49]. Although our research suggests 411 that BV ZEBRA and EA-D antibody levels may be associated with a reduced risk of NMO, 412 further studies are needed to confirm this. Based on the advantages of MR statistics, this 413 study suggests that EBV antibodies may provide new clues for NMO treatment. In 414 particular, for NMO patients with high levels of EBV antibodies, understanding the

415 different roles of different antibodies in the pathogenesis of NMO may facilitate the 416 exploration of personalised treatment approaches.

417 Current research on the association between HHV infection and the risk of MS has 418 yielded controversial results, [50-52], This controversy is reflected in the results of this 419 MR analysis. A meta-analysis found that CMV IgG seroprevalence was lower in people 420 with MS than in controls in Europe [53]. However, our study does not support a causal 421 relationship between CMV antibody immune response and risk of MS. Although one MR 422 study suggested a causal relationship between herpesvirus infection and MS, we did not

423 find a causal relationship between VZV gE and gI antibody levels and MS [18].

424 At present, the relationship between HHV and NMO is not very clear. Our study 425 suggests that HHV may be one of the important pathogens of NMO, and HHV 7 U14 426 antibody may be detrimental to NMO, but its exact pathogenic role in NMO requires 427 further investigation. VZV has been considered as a precursor infectious agent of NMO 428 [54-56], Causal association between chickenpox infection and NMO was also recently 429 confirmed by MR study [57], Our study further confirmed a causal effect of VZV gE and gI 430 antibody levels on NMO. VZV infection is an important risk factor for NMO, and 431 vaccination against VZV may help to reduce the risk of NMO. For NMO patients with high 432 levels of VZV gE and gI antibodies, the immune response and related pathogenic 433 mechanisms induced by VZV infection could potentially become a new therapeutic 434 approach.

435 Among 22 types of antibody immune response, only VZV gE and gI antibody levels 436 were found to be associated with MG. The resultant GWAS data from two different

437 datasets both confirm this causal association, suggesting that unlike in MS, the 438 pathogenic role of VZV in MG was robust, which may imply new therapeutic targets for 439 MG, especially for patients with high levels of this antibody.

440 This study has a number of important strengths. First, we effectively reduced the 441 influence of confounding factors and improved the accuracy and reliability of our results 442 by using a novel MR analysis method. Second, our comprehensive analysis explored the 443 causal relationships between 22 antibody immune responses to five herpesvirus 444 infections and five types of ANDs. This provided a detailed understanding of their 445 interactions. Third, we applied a rigorous correction procedure to ensure the robustness 446 and validity of our findings. For positive results, we cross-validated with additional 447 publicly available GWAS outcome data. We also conducted further meta-analyses to 448 resolve any inconsistencies. These measures helped to reduce the risk of false positives. 449 They also strengthened the credibility of our conclusions.

450 Although this study provides valuable insights, it has several limitations that should 451 be acknowledged. First, the use of summary level data in MR analyses, although 452 powerful, may introduce bias due to the assumption of linearity and the inability to 453 explore non-linear relationships. In addition, the generalisability of the findings is limited 454 by the demographic and genetic composition of the datasets used, which are 455 predominantly of European ancestry. This raises questions about the applicability of the 456 results to more diverse populations. Another limitation is the potential for pleiotropy, 457 where genetic variants used as instruments may affect the outcome through pathways 458 other than the exposure of interest, leading to biased estimates. Although we used

459 methods to mitigate pleiotropy, such as MR-PRESSO, the possibility of residual 460 confounding cannot be completely excluded. Finally, the study relies on the availability 461 and quality of existing GWAS datasets, which may vary in their coverage and accuracy of 462 antibody measurements, potentially affecting the robustness of the findings. Future 463 studies should aim to validate these findings in more diverse populations and with 464 individual-level data to better understand the complex relationships between herpesvirus 465 antibodies and autoimmune neurodegenerative diseases.

# <sup>466</sup> **Conlusion**

467 The results of this study reveal predicted causal effects of EBV EBNA-1 antibody, EBV 468 VCA p18 antibody on MS, HHV7 U14, VZV gE and gI antibody, EBV EA-D antibody and 469 EBV ZEBRA antibody on NMO, VZV gE and gI antibody on MG, This might suggest 470 potential role for above antibodies in the pathogenesis of ANDs, also This finding 471 highlights the need for further exploration into the specific mechanisms of above 472 antibodies in the pathophysiological processes of ANDs, providing an important 473 theoretical basis for the development of more effective treatment strategies in the future.

474

# <sup>475</sup> **Declarations**

#### <sup>476</sup> **Ethics approval and consent to participate**

477 Publicly available datasets were used for all data in our study. Informed consent was 478 obtained from all participants prior to enrollment, and ethical approval was obtained for 479 each cohort.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

#### It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

# <sup>481</sup> **Consent for Publication**

482 All authors provide their consent for the publication of this manuscript.

483

# <sup>484</sup> **Availability of data and materials**

485 The original papers presented in this study can be found in the supplementary materials.

486

## <sup>487</sup> **Competing Interests**

- 488 The authors declare that they have no competing interests. The research, data
- 489 interpretation, and conclusions presented in this manuscript were not influenced by any
- 490 financial, personal, or professional conflicts.

491

# <sup>492</sup> **Funding**

- 493 Grant from Science and Technology Program of Guangzhou: Key Lab of Guangzhou
- 494 Basic and Translational Research of Pan-vascular Diseases(202201020042);Youth
- 495 Pre-employment Training Programme Research Fund(2023ZC07); Natural Science
- 496 Foundation of Hunan Province Regional Joint Fund(2024JJ7012).

497

## <sup>498</sup> **Authors' contributions**

- 499 Sunjun Sun: Writing original draft, Visualization, Validation, Methodology, Formal
- 500 analysis, Funding acquisition;
- 501 Yiyong Wen: Writing- original draft, Formal analysis, review & editing;
- 502 Pan Tang: Writing– review & editing, Validation.

- 503 Fan Xie: Writing review & editing, Visualization, Validation.
- 504 Jun Wen: Writing review & editing, Supervision,
- 505 Anding Xu: Writing –Conceptualization, review & editing, Supervision, Funding
- 506 acquisition. Project administration.
- <sup>507</sup> **Acknowledgements**

508 The authors thank the Multiple Sclerosis Genetics Consortium and the International 509 Myasthenia Gravis Genomics Consortium, the UK Biobank and the FinnGen study for 510 providing publicly available MS, MG and GBS GWAS summary statistics for this analysis, 511 as well as the studies by Butler-Laporte G et al, Estrada K et al, Chia R et al, Jiang L et al 512 for antibody immune responses to five types of herpesvirus, NMO, MG, CIDP GWAS 513 summary statistics.

514

<sup>515</sup> **List of abbreviations**

516 ANDs: Autoimmune neuroinflammatory diseases , MS: multiple sclerosis, NMO: 517 neuromyelitis optica, GBS: Guillain-Barr é syndrome, CIDP: chronic inflammatory 518 demyelinating polyneuropathy, MG: myasthenia gravis. CNS: central nervous system, 519 PNS: peripheral nervous system, NJM: neuromuscular junction. EBV: Epstein-Barr virus; 520 HHV 6A: Human herpesvirus 6A; CMV: Cytomegalovirus; AQP4 IgG+ NMOSD: 521 aquaporin-4 antibody-positive NMO spectrum disord, MR: mendelian randomisation, 522 HSV: herpes simplex virus, EBNA-1: EBV encoded nuclear antigen-1, EBV-VCA p18: 523 EBV viral capsid antigen p18, VZV gE and gl: Varicella zoster virus glycoprotein E and I, 524 GWAS: Genome-Wide Association Study; IMSGC: International MS Genetics

525 Consortium; anti-AChR: anti-acetylcholine receptor antibodies; anti-MuSK: antibodies to 526 muscle-specific kinase; SNPs: single nucleotide polymorphisms; MAF: minor allele 527 frequencies; LD: linkage disequilibrium; BMI: body mass index; IVW: Inverse Variance 528 Weighte; IVs: instrumental variables (IVs); TSMR: Two-Sample MR; MR-PRESSO: MR 529 Egger intercept test and Outlier; OR: odds ratio; CSF: cerebrospinal fluid; EAE: 530 experimental autoimmune encephalomyelitis.

# **References**

 1. Khan AW, Farooq M, Hwang MJ, Haseeb M, Choi S. Autoimmune Neuroinflammatory Diseases: Role of Interleukins. Int J Mol Sci. 2023;24(9). Epub 20230427. doi: 10.3390/ijms24097960. PubMed PMID: 37175665; PubMed Central PMCID: PMCPMC10178921.

 2. Bhagavati S. Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy. Front Neurol. 2021;12:664664. Epub 20210414. doi: 10.3389/fneur.2021.664664. PubMed PMID: 33935958; PubMed Central PMCID: PMCPMC8079742.

 3. Zarobkiewicz MK, Morawska I, Michalski A, Roliński J, Bojarska-Junak A. NKT and NKT- like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome. Int J Mol Sci. 2021;22(17). Epub 20210901. doi: 10.3390/ijms22179520. PubMed PMID: 34502425; PubMed Central PMCID: PMCPMC8431671.

 4. Gogia B, Rocha Cabrero F, Khan Suheb MZ, Lui F, Rai PK. Chronic Inflammatory Demyelinating Polyradiculoneuropathy. StatPearls. Treasure Island (FL): StatPearls

- Publishing
- Copyright © 2024, StatPearls Publishing LLC.; 2024.
- 5. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an
- urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr
- Opin Immunol. 2023;80:102266. Epub 20221126. doi: 10.1016/j.coi.2022.102266. PubMed
- PMID: 36446151; PubMed Central PMCID: PMCPMC9918670.
- 6. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509-24.
- Epub 20230510. doi: 10.1038/s41581-023-00720-1. PubMed PMID: 37165096; PubMed
- Central PMCID: PMCPMC10171171.
- 7. Bjornevik K, Münz C, Cohen JI, Ascherio A. Epstein-Barr virus as a leading cause of

multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19(3):160-71. Epub

- 
- 20230209. doi: 10.1038/s41582-023-00775-5. PubMed PMID: 36759741.
- 8. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301. Epub 20220113. doi: 10.1126/science.abj8222. PubMed PMID: 35025605.

 9. Miao Y, Shi Z, Zhang W, Zhu L, Tang S, Chen H, et al. Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm. 2023;10(5). Epub 20230706. doi: 10.1212/nxi.0000000000200134. PubMed PMID: 37414573; PubMed Central PMCID: PMCPMC10326831.

10. Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology and management.

 Drugs. 2004;64(6):597-610. doi: 10.2165/00003495-200464060-00003. PubMed PMID: 15018590.

11. Rodríguez Y, Vatti N, Ramírez-Santana C, Chang C, Mancera-Páez O, Gershwin ME,

Anaya JM. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J

Autoimmun. 2019;102:8-37. Epub 20190506. doi: 10.1016/j.jaut.2019.04.021. PubMed PMID:

31072742.

12. Kakalacheva K, Maurer MA, Tackenberg B, M ü nz C, Willcox N, L ü nemann JD.

Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann

Neurol. 2011;70(3):508-14. doi: 10.1002/ana.22488. PubMed PMID: 21905082.

13. Cavalcante P, Marcuzzo S, Franzi S, Galbardi B, Maggi L, Motta T, et al. Epstein-Barr

virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an

autoimmunity mediator? Oncotarget. 2017;8(56):95432-49. Epub 20170908. doi:

10.18632/oncotarget.20731. PubMed PMID: 29221139; PubMed Central PMCID:

PMCPMC5707033.

 14. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology.

Stat Med. 2008;27(8):1133-63. doi: 10.1002/sim.3034. PubMed PMID: 17886233.

15. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to

understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22. doi:

10.1093/ije/dyg070. PubMed PMID: 12689998.

16. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent

Developments in Mendelian Randomization Studies. Curr Epidemiol Rep. 2017;4(4):330-45.

Epub 20171122. doi: 10.1007/s40471-017-0128-6. PubMed PMID: 29226067; PubMed

Central PMCID: PMCPMC5711966.

- 17. Zhang W, Wu P, Yin R, Sun M, Zhang R, Liao X, et al. Mendelian Randomization
- Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis.
- Front Neurosci. 2022;16:817067. Epub 20220301. doi: 10.3389/fnins.2022.817067. PubMed

PMID: 35299622; PubMed Central PMCID: PMCPMC8920987.

18. Zhu G, Zhou S, Xu Y, Gao R, Zhang M, Zeng Q, et al. Chickenpox and multiple sclerosis:

A Mendelian randomization study. J Med Virol. 2023;95(1):e28315. Epub 20221123. doi:

- 10.1002/jmv.28315. PubMed PMID: 36380510.
- 19. Butler-Laporte G, Kreuzer D, Nakanishi T, Harroud A, Forgetta V, Richards JB. Genetic
- Determinants of Antibody-Mediated Immune Responses to Infectious Diseases Agents: A
- Genome-Wide and HLA Association Study. Open Forum Infect Dis. 2020;7(11):ofaa450.
- Epub 20200924. doi: 10.1093/ofid/ofaa450. PubMed PMID: 33204752; PubMed Central
- PMCID: PMCPMC7641500.
- 20. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in
- susceptibility. Science. 2019;365(6460). doi: 10.1126/science.aav7188. PubMed PMID:
- 31604244; PubMed Central PMCID: PMCPMC7241648.
- 21. Estrada K, Whelan CW, Zhao F, Bronson P, Handsaker RE, Sun C, et al. A whole-
- genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun.
- 2018;9(1):1929. Epub 20180516. doi: 10.1038/s41467-018-04332-3. PubMed PMID:
- 29769526; PubMed Central PMCID: PMCPMC5955905.
- 22. Chia R, Saez-Atienzar S, Murphy N, Chi ò A, Blauwendraat C, Roda RH, et al.

 Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022;119(5). doi: 10.1073/pnas.2108672119. PubMed PMID: 35074870; PubMed Central PMCID: PMCPMC8812681.

23. Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for

biobank-scale data. Nat Genet. 2021;53(11):1616-21. Epub 20211104. doi: 10.1038/s41588-

021-00954-4. PubMed PMID: 34737426.

24. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with

 multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-65. Epub 20130920. doi: 10.1002/gepi.21758. PubMed PMID: 24114802; PubMed Central PMCID:

PMCPMC4377079.

 25. Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, et al. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS One. 2015;10(4):e0120758. Epub 20150421. doi: 10.1371/journal.pone.0120758. PubMed PMID: 25898129; PubMed Central PMCID: PMCPMC4405269.

 26. Sekula P, Del Greco MF, Pattaro C, Köttgen A. Mendelian Randomization as an Approach to Assess Causality Using Observational Data. J Am Soc Nephrol. 2016;27(11):3253-65. Epub 20160802. doi: 10.1681/asn.2016010098. PubMed PMID: 27486138; PubMed Central PMCID: PMCPMC5084898.

 27. Sedgwick P. Multiple hypothesis testing and Bonferroni's correction. Bmj. 2014;349:g6284. Epub 20141020. doi: 10.1136/bmj.g6284. PubMed PMID: 25331533.



- 
- Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins. J Neuroimmunol.
- 2016;299:147-51. Epub 20160831. doi: 10.1016/j.jneuroim.2016.08.016. PubMed PMID:
- 27725113.

31. Huang J, Tengvall K, Bomfim Lima I, Hedström AK, Butt J, Brenner N, et al. Genetics of

immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis. Brain.

2024. Epub 20240417. doi: 10.1093/brain/awae110. PubMed PMID: 38630618.

32. Domínguez-Mozo MI, López-Lozano L, Pérez-Pérez S, García-Martínez Á, Torrejón MJ,

Arroyo R, Álvarez-Lafuente R. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort:

A two-years longitudinal study. Front Immunol. 2022;13:991662. Epub 20220914. doi:

- 10.3389/fimmu.2022.991662. PubMed PMID: 36189297; PubMed Central PMCID:
- PMCPMC9515943.

 33. Bray PF, Luka J, Bray PF, Culp KW, Schlight JP. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology. 1992;42(9):1798-804. doi:

10.1212/wnl.42.9.1798. PubMed PMID: 1381067.

- 34. Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321-7.
- Epub 20220124. doi: 10.1038/s41586-022-04432-7. PubMed PMID: 35073561; PubMed
- Central PMCID: PMCPMC9382663.
- 35. Kyllesbech C, Trier N, Slibinskas R, Ciplys E, Tsakiri A, Frederiksen JL, Houen G. Virus- specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis. J Neuroimmunol. 2022;367:577868. Epub 20220418. doi:
- 10.1016/j.jneuroim.2022.577868. PubMed PMID: 35477126.
- 36. Lindsey JW. Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react
- with human proteins. J Neuroimmunol. 2017;310:131-4. Epub 20170720. doi: 10.1016/j.jneuroim.2017.07.013. PubMed PMID: 28778437.
- 37. Kuhlenbäumer G, Hannibal MC, Nelis E, Schirmacher A, Verpoorten N, Meuleman J, et
- al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat Genet.

2005;37(10):1044-6. Epub 20050925. doi: 10.1038/ng1649. PubMed PMID: 16186812.

- 38. Mao H, Liu J, Shi W, Huang Q, Xu X, Ni L, et al. The expression patterns of Septin-9
- after traumatic brain injury in rat brain. J Mol Neurosci. 2013;51(2):558-66. Epub 20130523.
- doi: 10.1007/s12031-013-0024-6. PubMed PMID: 23700216.
- 39. Tengvall K, Huang J, Hellström C, Kammer P, Biström M, Ayoglu B, et al. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci U S A. 2019;116(34):16955-60. Epub 20190802. doi: 10.1073/pnas.1902623116. PubMed PMID: 31375628; PubMed Central PMCID:

PMCPMC6708327.

40. Sherbet GV. Molecular Approach to Targeted Therapy for Multiple Sclerosis. CNS Neurol

Disord Drug Targets. 2016;15(1):20-34. doi: 10.2174/1871527315666151110125840.

PubMed PMID: 26560895.

 41. Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH. Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e466. Epub 20180607. doi: 10.1212/nxi.0000000000000466.

PubMed PMID: 29892607; PubMed Central PMCID: PMCPMC5994704.

42. Osipova-Goldberg HI, Turchanowa LV, Adler B, Pfeilschifter JM. H2O2 inhibits BCR-

dependent immediate early induction of EBV genes in Burkitt's lymphoma cells. Free Radic

Biol Med. 2009;47(8):1120-9. Epub 20090621. doi: 10.1016/j.freeradbiomed.2009.06.019.

PubMed PMID: 19540913.

43. Maple PAC, Gran B, Tanasescu R, Pritchard DI, Constantinescu CS. An Absence of

Epstein-Barr Virus Reactivation and Associations with Disease Activity in People with Multiple

Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines (Basel). 2020;8(3). Epub

20200828. doi: 10.3390/vaccines8030487. PubMed PMID: 32872342; PubMed Central

PMCID: PMCPMC7564729.

 44. Torkildsen Ø, Nyland H, Myrmel H, Myhr KM. Epstein-Barr virus reactivation and multiple sclerosis. Eur J Neurol. 2008;15(1):106-8. Epub 20071127. doi: 10.1111/j.1468- 1331.2007.02009.x. PubMed PMID: 18042233.

 45. Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A, Banwell B. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology. 2013;81(16):1392-9.

- Epub 20130906. doi: 10.1212/WNL.0b013e3182a841e4. PubMed PMID: 24014504; PubMed
- Central PMCID: PMCPMC3806908.
- 46. Massa J, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Plasma titers of antibodies against
- Epstein-Barr virus BZLF1 and risk of multiple sclerosis. Neuroepidemiology. 2007;28(4):214-5.
- Epub 20070911. doi: 10.1159/000108113. PubMed PMID: 17851260.
- 47. Masuda S, Mori M, Arai K, Uzawa A, Muto M, Uchida T, et al. Epstein-Barr virus
- persistence and reactivation in neuromyelitis optica. J Neurol Neurosurg Psychiatry.
- 2015;86(10):1137-42. Epub 20141128. doi: 10.1136/jnnp-2014-308095. PubMed PMID:
- 25433035.
- 48. Shi Z, Kong L, Wang R, Wang X, Wang Z, Luo W, et al. Cytomegalovirus and Epstein-
- Barr virus infections in patients with neuromyelitis optica spectrum disorder. J Neurol. 2024.

Epub 20240724. doi: 10.1007/s00415-024-12571-2. PubMed PMID: 39046523.

- 49. Graves J, Grandhe S, Weinfurtner K, Krupp L, Belman A, Chitnis T, et al. Protective environmental factors for neuromyelitis optica. Neurology. 2014;83(21):1923-9. Epub 20141022. doi: 10.1212/wnl.0000000000001001. PubMed PMID: 25339213; PubMed Central PMCID: PMCPMC4248458.
- 50. Merelli E, Bedin R, Sola P, Barozzi P, Mancardi GL, Ficarra G, Franchini G. Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and children. J Neurol. 1997;244(7):450-4. doi: 10.1007/s004150050121. PubMed PMID: 9266465.
- 51. Nora-Krukle Z, Chapenko S, Logina I, Millers A, Platkajis A, Murovska M. Human herpesvirus 6 and 7 reactivation and disease activity in multiple sclerosis. Medicina (Kaunas).

2011;47(10):527-31. PubMed PMID: 22186115.

 52. Khalesi Z, Tamrchi V, Razizadeh MH, Letafati A, Moradi P, Habibi A, et al. Association between human herpesviruses and multiple sclerosis: A systematic review and meta-analysis. Microb Pathog. 2023;177:106031. Epub 20230210. doi: 10.1016/j.micpath.2023.106031. PubMed PMID: 36775211. 53. Thakolwiboon S, Zhao-Fleming H, Karukote A, Pachariyanon P, Williams HG, Avila M. Regional differences in the association of cytomegalovirus seropositivity and multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2020;45:102393. Epub 20200712. doi: 10.1016/j.msard.2020.102393. PubMed PMID: 32683307. 54. Heerlein K, Jarius S, Jacobi C, Rohde S, Storch-Hagenlocher B, Wildemann B. Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci. 2009;276(1-2):184-6. Epub 20080920. doi: 10.1016/j.jns.2008.08.015. PubMed PMID: 18805556. 55. Sellner J, Hemmer B, M ü hlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun. 2010;34(4):371-9. Epub

20091022. doi: 10.1016/j.jaut.2009.09.013. PubMed PMID: 19853412.

 56. Machado C, Amorim J, Rocha J, Pereira J, Lourenço E, Pinho J. Neuromyelitis optica spectrum disorder and varicella-zoster infection. J Neurol Sci. 2015;358(1-2):520-1. Epub 20151004. doi: 10.1016/j.jns.2015.09.374. PubMed PMID: 26440423.

 57. Wang L, Zhou L, ZhangBao J, Huang W, Tan H, Fan Y, et al. Causal associations between prodromal infection and neuromyelitis optica spectrum disorder: A Mendelian randomization study. Eur J Neurol. 2023;30(12):3819-27. Epub 20230816. doi:

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316542;](https://doi.org/10.1101/2024.10.31.24316542) this version posted November 2, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

745 10.1111/ene.16014. PubMed PMID: 37540821.



Fig 1DMR estimate results of antibodies of five herpesviridae viri



Fig 2 MR estimate results of antibodies of five herpesviridae viru



Fig 3 MR estimate results of antibodies of five herpesviridae viru



Fig 4 MR estimate results of antibodies of five herpesviridae viru



Fig 5 MR estimate results of antibodies of five herpesviridae viru